Categories
Change Password!
Reset Password!
Dienogest significantly shrinks ovarian endometriomas and alleviates pain, with minimal side effects and no impact on liver, kidney, or coagulation functions.
Ovarian endometriomas (OMA) are common in women with endometriosis, causing chronic pain and fertility issues. Dienogest, a progestin, has been increasingly used to manage these cysts and a recent study studied its long-term impact on cyst size and symptoms and found evidence for its effectiveness.
The study retrospectively analyzed clinical data from 75 patients suffering from OMA who received Dienogest (2 mg/day). The analysis focused on changes in OMA volume, visual analogue scale (VAS) scores for endometriosis-related pain, and alterations in blood biological markers, liver and kidney function, coagulation function, and breast changes before and after therapy. OMA cyst volume decreased by 36% at 3 months, 56% at 6 months, and 77.6% at 12 months. Pain (VAS score) dropped to 0 mm across all follow-up points.
Levels of blood cancer antigen 125 (CA125) and cancer antigen 19-9 (CA19-9) showed a consistent decline throughout the treatment period. No significant changes were noted in hepatic, renal, or coagulation functions. During follow-up, a few patients showed changes in nodule growth or lesion type, but no breast cancer or precancerous lesions were detected. Dienogest proved to be an effective option for managing OMA, reducing both cyst volume and pain while maintaining overall organ health.
Zhonghua fu chan ke za zhi (Chinese Journal of Obstetrics and Gynecology)
Efficacy and safety of dienogest on ovarian endometrioma
J F Sun et al.
Comments (0)